INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 8 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $11,397,000 | +8.2% | 17,435,000 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $10,534,000 | 0.0% | 17,435,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $10,534,000 | -3.8% | 17,435,000 | -4.7% | 0.00% | 0.0% |
| Q3 2021 | $10,953,000 | -9.7% | 18,294,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $12,131,000 | +2.3% | 18,294,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $11,858,000 | +7.0% | 18,294,000 | -1.8% | 0.00% | 0.0% |
| Q4 2020 | $11,087,000 | +24.0% | 18,622,000 | +43.2% | 0.00% | 0.0% |
| Q3 2020 | $8,940,000 | -4.2% | 13,005,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $9,330,000 | +87.8% | 13,005,000 | +122.8% | 0.00% | 0.0% |
| Q1 2020 | $4,967,000 | -27.9% | 5,838,000 | +12.1% | 0.00% | 0.0% |
| Q4 2019 | $6,892,000 | +47.2% | 5,209,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $4,682,000 | -6.3% | 5,209,000 | +3.2% | 0.00% | 0.0% |
| Q2 2019 | $4,995,000 | – | 5,048,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
| PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
| Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
| Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
| Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
| Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
| Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
| CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |